Antithrombin deficiency, whether inherited or acquired, poses a significant risk factor for venous thromboembolism (VTE) by impairing the natural regulation of coagulation. As a critical plasma ...

DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck Inc., a wholly owned subsidiary of H. Lundbeck A/S in Denmark (LUN: Copenhagen Stock Exchange), announced today that ATryn ® (Antithrombin [Recombinant]) is ...

INNOVANCE Antithrombin assay is a cutting-edge, ready-to-use chromogenic reagent for the automated determination of antithrombin (AT) activity. It is highly accurate even at low activity levels and ...

FRAMINGHAM, Mass.--(BUSINESS WIRE)--rEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies which demonstrate that pregnant patients with ...

December 21, 2007 -- The US Food and Drug Administration (FDA) has granted orphan drug designation to CDX-110 for the treatment of glioblastoma multiforme, ATryn for the treatment of hereditary ...

In June 2021, Kenneth A. Bauer, MD, from Beth Israel Deaconess Medical Center and professor of medicine at Harvard Medical School, spoke with Healio about the diagnosis and treatment of hereditary ...

When to treat patients with heparin and when to treat using an antithrombin concentrate; Why it is important to aggressively treat patients with type one antithrombin deficiency who have already ...

Hereditary antithrombin (AT) deficiency — an autosomal dominant disorder caused by SERPINC1 gene mutations — carries a high risk of venous thromboembolism. Treatment requires the long-term use of oral ...

The authors review 8 cases of thrombosis in uncommon sites caused by protein S deficiency. Hypercoagulability, venous stasis, and vessel wall injury predispose to thrombus formation. Thrombophilia can ...

Antithrombin III (human) 500 IU; per vial; lyophilized pwd for IV infusion after reconstitution; preservative-free. Antithrombin, an alpha2-glycoprotein, is normally present in human plasma and is the ...